The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?
Open accessAbstract
Recent immunohistological and imaging studies emphasize the crucial role of axonal injury in determining the extent of permanent neurological deficits in patients with multiple sclerosis. We have recently shown that human immune cells are capable of producing the neurotrophin brain-derived neurotrophic factor (BDNF), which can prevent axonal and neuronal damage after various pathological insults. BDNF imported into the CNS by immune cells would thus be an attractive candidate for mediating neuroprotective effects in multiple sclerosis. The aim of the present study was to perform a detailed immunohistochemical analysis of the expression of BDNF and its receptor truncated trkB tyrosine kinase receptor (gp145trkB) in a series of multiple sclerosis brain lesions. Our data show that various types of neurones throughout the brain are BDNF immunopositive in multiple sclerosis patients as well as in controls. Furthermore, in multiple sclerosis lesions, BDNF is primarily present in immune cells (T cells, macrophages/microglia) and reactive astrocytes. The number of BDNF immunopositive cells correlates with lesional demyelinating activity. The BDNF receptor gp145trkB is found in neurones in the immediate vicinity of multiple sclerosis plaques as well as in reactive astrocytes within the lesion, but not in immune cells. Our results demonstrate that both BDNF and gp145trkB are expressed in multiple sclerosis lesions. This suggests that BDNF and gp145trkB are involved in immune-mediated neuroprotective interactions in multiple sclerosis, and supports the concept that immune cells produce both damaging and protective factors in multiple sclerosis lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Physiology of the Neurotrophins
Lewin, G. R., & Barde, Y.-A. (1996) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.19.030196.001445 · Cited by 1,955
REGULATION OF IMMUNE RESPONSES BY TGF-β
Letterio, J. J., & Roberts, A. B. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.137 · Cited by 1,890
Axonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287 · cited 1×
“…into sites of neural injury seem to protect brainstem neurones after experimental trauma (Serpe et al., 1999) and could potentially do so in neurodegenerative diseases (Batchelor et al., 1999), which show substantial immune activation in foci of pathological change (McGeer and McGeer, 1995).”
BackgroundKerschensteiner, M., Gallmeier, E., Behrens, L., Leal, V. V., Misgeld, T., Klinkert, W. E. F., Kolbeck, R., Hoppe, E., Oropeza-Wekerle, R.-L., Bartke, I., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.865 · Cited by 1,019
Self-citationRegional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain.
Hofer, M., Pagliusi, S. R., Hohn, A., Leibrock, J., & Barde, Y. A. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07423.x · Cited by 1,017
Klein, R., Nanduri, V., Jing, S., Lamballe, F., Tapley, P., Bryant, S., Cordon-Cardo, C., Jones, K. R., Reichardt, L. F., & Barbacid, M. (1991) · Cell · doi:10.1016/0092-8674(91)90628-c · Cited by 958
Bruce, A. J., Boling, W., Kindy, M. S., Peschon, J., Kraemer, P. J., Carpenter, M. K., Holtsberg, F. W., & Mattson, M. P. (1996) · Nature Medicine · doi:10.1038/nm0796-788 · Cited by 932
Acute axonal injury in multiple sclerosis: Correlation with demyelination and inflammation
Bitsch, A. (2000) · Brain · doi:10.1093/brain/123.6.1174 · Cited by 898
Cited by
Microglia: Active sensor and versatile effector cells in the normal and pathologic brain
Hanisch, U.-K., & Kettenmann, H. (2007) · Nature Neuroscience · doi:10.1038/nn1997 · Cited by 3,676
Microglial physiology: unique stimuli, specialized responses
Ransohoff, R. M., & Perry, V. H. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132528 · Cited by 1,858
The therapeutic potential of neural stem cells
Martino, G., & Pluchino, S. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1908 · Cited by 744
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Coles, A. J., Cox, A., Page, E., Jones, J., Trip, S. A., Deans, J., Seaman, S., Miller, D. H., Hale, G., Waldmann, H., et al. (2006) · Journal of Neurology · doi:10.1007/s00415-005-0934-5 · Cited by 506
Bidirectional Microglia–Neuron Communication in Health and Disease
Szepesi, Z., Manouchehrian, O., Bachiller, S., & Deierborg, T. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00323 · Cited by 459
Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis
Dutta, R., & Trapp, B. D. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.09.005 · Cited by 457
Pathology of Demyelinating Diseases
Popescu, B. F. G., & Lucchinetti, C. F. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132443 · Cited by 397
The Role of Astrocytes in Multiple Sclerosis
Ponath, G., Park, C., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00217 · Cited by 359
Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice
Zhang, J., Li, Y., Chen, J., Cui, Y., Lu, M., Elias, S. B., Mitchell, J. B., Hammill, L., Vanguri, P., & Chopp, M. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.03.018 · Cited by 341
Microglia-Mediated Inflammation and Neurodegenerative Disease
Xu, L., He, D., & Bai, Y. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9593-4 · Cited by 332
Microglia Control Neuronal Network Excitability via BDNF Signalling
Ferrini, F., & De Koninck, Y. (2013) · Neural Plasticity · doi:10.1155/2013/429815 · Cited by 318
Extensive cortical remyelination in patients with chronic multiple sclerosis
Albert, M., Antel, J., Brück, W., & Stadelmann, C. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2006.00043.x · Cited by 314
Self-citationPathology of multiple sclerosis and related inflammatory demyelinating diseases
(2014) · Handbook of Clinical Neurology · doi:10.1016/b978-0-444-52001-2.00002-9 · Cited by 303
Gold, S. M., Schulz, K.-H., Hartmann, S., Mladek, M., Lang, U. E., Hellweg, R., Reer, R., Braumann, K.-M., & Heesen, C. (2003) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(03)00121-8 · Cited by 300
Brück, W. (2005) · Journal of Neurology · doi:10.1007/s00415-005-5002-7 · Cited by 300
Self-citationEstrogen–BDNF interactions: Implications for neurodegenerative diseases
Sohrabji, F., & Lewis, D. K. (2006) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2006.09.003 · Cited by 287
London, A., Cohen, M., & Schwartz, M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00034 · Cited by 282
Pathogenic role of glial cells in Parkinson's disease
Teismann, P., Tieu, K., Cohen, O., Choi, D., Wu, D. C., Marks, D., Vila, M., Jackson‐Lewis, V., & Przedborski, S. (2003) · Movement Disorders · doi:10.1002/mds.10332 · Cited by 275
Kerschensteiner, M., Stadelmann, C., Dechant, G., Wekerle, H., & Hohlfeld, R. (2003) · Annals of Neurology · doi:10.1002/ana.10446 · Cited by 273
Self-citationZiemssen, T. (2002) · Brain · doi:10.1093/brain/awf252 · Cited by 268
The astrocyte in multiple sclerosis revisited
Brosnan, C. F., & Raine, C. S. (2013) · Glia · doi:10.1002/glia.22443 · Cited by 259
Brambilla, R. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01980-7 · Cited by 246
Macrophage subsets and microglia in multiple sclerosis
Bogie, J. F. J., Stinissen, P., & Hendriks, J. J. A. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1310-2 · Cited by 251
Microglia and mast cells: two tracks on the road to neuroinflammation
Skaper, S. D., Giusti, P., & Facci, L. (2012) · The FASEB Journal · doi:10.1096/fj.11-197194 · Cited by 235
Meeuwsen, S., Persoon‐Deen, C., Bsibsi, M., Ravid, R., & Noort, J. M. V. (2003) · Glia · doi:10.1002/glia.10259 · Cited by 185
Glatiramer acetate: Mechanisms of action in multiple sclerosis
Schrempf, W., & Ziemssen, T. (2007) · Autoimmunity Reviews · doi:10.1016/j.autrev.2007.02.003 · Cited by 168
Olechowski, C. J., Truong, J. J., & Kerr, B. J. (2009) · Pain · doi:10.1016/j.pain.2008.11.002 · Cited by 159
Immunomodulatory activity of interferon‐beta
Kasper, L. H., & Reder, A. T. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.84 · Cited by 159
Colombo, E., Cordiglieri, C., Melli, G., Newcombe, J., Krumbholz, M., Parada, L. F., Medico, E., Hohlfeld, R., Meinl, E., & Farina, C. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20110698 · Cited by 146
Self-citationGlatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen, T., & Schrempf, W. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79024-4 · Cited by 135
Burbach, G. J., Hellweg, R., Haas, C. A., Del Turco, D., Deicke, U., Abramowski, D., Jucker, M., Staufenbiel, M., & Deller, T. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.5599-03.2004 · Cited by 132
Remyelinating strategies for the treatment of multiple sclerosis
Stangel, M., & Hartung, H.-P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00105-3 · Cited by 126
Imaging of microglia in patients with neurodegenerative disorders
Politis, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00096 · Cited by 111
Vereyken, E. J., Heijnen, P. D., Baron, W., de Vries, E. H., Dijkstra, C. D., & Teunissen, C. E. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-58 · Cited by 108
van Rossum, D., Hilbert, S., Straßenburg, S., Hanisch, U., & Brück, W. (2008) · Glia · doi:10.1002/glia.20611 · Cited by 66
Self-citationSubstantial early, but nonprogressive neuronal loss in multiple sclerosis (ms) spinal cord
Schirmer, L., Albert, M., Buss, A., Schulz‐Schaeffer, W. J., Antel, J. P., Brück, W., & Stadelmann, C. (2009) · Annals of Neurology · doi:10.1002/ana.21799 · Cited by 56
Self-citationWong, A. W., Giuffrida, L., Wood, R., Peckham, H., Gonsalvez, D., Murray, S. S., Hughes, R. A., & Xiao, J. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.10.002 · Cited by 39
Differential effects of Th1 and Th2 lymphocyte supernatants on human microglia
Séguin, R., Biernacki, K., Prat, A., Wosik, K., Kim, H., Blain, M., Mccrea, E., Bar‐Or, A., & Antel, J. P. (2003) · Glia · doi:10.1002/glia.10201 · Cited by 40
Venkatesha, S. H., & Moudgil, K. D. (2019) · Inflammation Research · doi:10.1007/s00011-019-01219-x · Cited by 36
The relevance of BDNF for neuroprotection and neuroplasticity in multiple sclerosis
Maiworm, M. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1385042 · Cited by 27
Ksiazek-Winiarek, D., Szpakowski, P., Turniak, M., Szemraj, J., & Glabinski, A. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0981-2 · Cited by 26
Remyelinating and neuroprotective treatments in multiple sclerosis
Stangel, M. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.4.331 · Cited by 22
Metadata
- Authors
- Stadelmann, C., Kerschensteiner, M., Misgeld, T., Brück, W., Hohlfeld, R., & Lassmann, H.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-01-01
- Volume
- 125
- Issue
- 1
- Pages
- 75-85
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2133005541
- Cited by
- 425
- References
- 70
- FWCI
- 17.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.